



December 5, 2016

## **Peregrine to Report Financial Results for Second Quarter of Fiscal Year 2017 After Market Close on December 12, 2016**

TUSTIN, Calif., Dec. 05, 2016 (GLOBE NEWSWIRE) -- Peregrine Pharmaceuticals, Inc. (NASDAQ:PPHM) (NASDAQ:PPHMP), a biopharmaceutical company committed to improving patient lives by manufacturing high quality products for biotechnology and pharmaceutical companies and advancing its proprietary R&D pipeline, today announced that it will report financial results for the second quarter of fiscal year 2017 ended October 31, 2016 on December 12, 2016 after market close and will host a conference call and webcast at 1:30 PM Pacific Time (4:30 PM Eastern Time). Peregrine's senior management will discuss financial results for the second quarter and review recent corporate developments.

To listen to the live webcast, or access the archived webcast, please visit: <http://ir.peregrineinc.com/events.cfm>.

To listen to the conference call, please dial (877) 312-5443 or (253) 237-1126 and request the Peregrine Pharmaceuticals call.

### **About Peregrine Pharmaceuticals, Inc.**

Peregrine Pharmaceuticals, Inc. is a biopharmaceutical company committed to improving the lives of patients by delivering high quality pharmaceutical products through its contract development and manufacturing organization (CDMO) services and through advancing and licensing its investigational immunotherapy and related products. Peregrine's in-house CDMO services, including cGMP manufacturing and development capabilities, are provided through its wholly-owned subsidiary Avid Bioservices, Inc. ([www.avidbio.com](http://www.avidbio.com)), which provides development and biomanufacturing services for both Peregrine and third-party customers. The company is also working to evaluate its lead immunotherapy candidate, bavituximab, in combination with immune stimulating therapies for the treatment of various cancers, and developing its proprietary exosome technology for the detection and monitoring of cancer. For more information, please visit [www.peregrineinc.com](http://www.peregrineinc.com).

#### Contacts:

Jay Carlson

Peregrine Pharmaceuticals, Inc.

(800) 987-8256

[info@peregrineinc.com](mailto:info@peregrineinc.com)

Stephanie Diaz (Investors)

Vida Strategic Partners

415-675-7401

[sdiaz@vidasp.com](mailto:sdiaz@vidasp.com)

Tim Brons (Media)

Vida Strategic Partners

415-675-7402

[tbrons@vidasp.com](mailto:tbrons@vidasp.com)

 Primary Logo

Source: Peregrine Pharmaceuticals Inc.

News Provided by Acquire Media